Evonik Industries AG/ADR
No enriched coverage for $EVKIF in the last 7 days.
No SEC Form 4 filings for $EVKIF in the last 30 days.
See all $EVKIF insider activity →Evonik Industries' shares rose 2.6% after Reuters reported BASF may submit a new takeover offer. BASF's initial offer of €22.15 per share was rejected in September. Citi analysts estimate a potential €25 per share offer could boost BASF's earnings and cash flow by 20% through 2030, but may reduce return on invested capital to 9%.
Germany's RAG Foundation, which owns ~44% of Evonik, removed its 25.1% veto floor, allowing potential sale of its stake. BASF is exploring a takeover. Evonik's dividend policy change and RAG's financial needs are key factors. BASF aims to expand its specialty chemicals portfolio. Regulatory scrutiny expected.
Evonik Industries AG (EVKIF.PK) rejected a 10.3 billion euro acquisition offer from BASF SE (BAS.DE) as it was deemed too low. BASF offered 22.15 euros per share, valuing Evonik at 14.2 billion euros. Evonik's market cap is 8.4 billion euros, and its enterprise value is around 12 billion euros. Combined revenues of both companies were 74 billion euros last year. Evonik's shares were down 1.28 percent on the Frankfurt Exchange.
Recent EVKIF coverage spans mergers & acquisitions and market movers.
Evonik Industries' shares rose 2.6% after Reuters reported BASF may submit a new takeover offer. BASF's initial offer of €22.15 per share was rejected in September. Citi analysts estimate a potential €25 per share offer could boost BASF's earnings and cash flow by 20% through 2030, but may reduce return on invested capital to 9%.
Germany's RAG Foundation, which owns ~44% of Evonik, removed its 25.1% veto floor, allowing potential sale of its stake. BASF is exploring a takeover. Evonik's dividend policy change and RAG's financial needs are key factors. BASF aims to expand its specialty chemicals portfolio. Regulatory scrutiny expected.
Evonik likely faces downward pressure as the deal collapse removes a premium‑priced acquisition prospect.
Evonik Industries' stock surged 8.1% to €19.54 after BASF SE reportedly proposed a merger, aiming to create a €74B European chemicals giant. Evonik's valuation is €12B including debt. The move follows Evonik's recent struggles, including a 52-week low of €12.49. BASF's approach is part of its strategy to streamline operations and focus on higher-margin businesses.
Evonik Industries' stock rose 2.8% to €17.73 after announcing a transformation plan to cut 3,200 jobs by 2029, reorganize its portfolio, and explore investments in Asia and the Americas. The company also plans to divest two units, Syneqt and Oxeno, and will avoid compulsory redundancies. This follows a recent downgrade by Morgan Stanley.
AlphAI scores every news story that mentions EVKIF with an AI model for sentiment and relevance, and aggregates insider trades from Evonik Industries AG/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Evonik Industries' shares rose 2.6% after Reuters reported BASF may submit a new takeover offer. BASF's initial offer of €22.15 per share was rejected in September. Citi analysts estimate a potential €25 per share offer could boost BASF's earnings and cash flow by 20% through 2030, but may reduce return on invested capital to 9%.
2 min readGermany's RAG Foundation, which owns ~44% of Evonik, removed its 25.1% veto floor, allowing potential sale of its stake. BASF is exploring a takeover. Evonik's dividend policy change and RAG's financial needs are key factors. BASF aims to expand its specialty chemicals portfolio. Regulatory scrutiny expected.
3 min readEvonik Industries AG (EVKIF.PK) rejected a 10.3 billion euro acquisition offer from BASF SE (BAS.DE) as it was deemed too low. BASF offered 22.15 euros per share, valuing Evonik at 14.2 billion euros. Evonik's market cap is 8.4 billion euros, and its enterprise value is around 12 billion euros. Combined revenues of both companies were 74 billion euros last year. Evonik's shares were down 1.28 percent on the Frankfurt Exchange.
2 min readEvonik Industries' stock surged 8.1% to €19.54 after BASF SE reportedly proposed a merger, aiming to create a €74B European chemicals giant. Evonik's valuation is €12B including debt. The move follows Evonik's recent struggles, including a 52-week low of €12.49. BASF's approach is part of its strategy to streamline operations and focus on higher-margin businesses.
2 min readEvonik Industries' stock rose 2.8% to €17.73 after announcing a transformation plan to cut 3,200 jobs by 2029, reorganize its portfolio, and explore investments in Asia and the Americas. The company also plans to divest two units, Syneqt and Oxeno, and will avoid compulsory redundancies. This follows a recent downgrade by Morgan Stanley.
2 min read
